AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

IL-23 Inhibitors May Better Prevent Psoriatic Arthritis Than IL-17 Blockers

Description

The speaker argues that IL-23 inhibitors are more likely than IL-17 blockers to prevent the development of psoriatic arthritis, while acknowledging that IL-17 blockers may be better for treating established psoriatic arthritis. The talk emphasizes dermatologists’ role in identifying patients at risk before arthritis develops, noting risk factors such as obesity, joint pain, severe psoriasis, nail and scalp psoriasis, uveitis, family history, and musculoskeletal symptoms. The speaker explains the biologic rationale that IL-23 sits upstream of IL-17 and acts as a master regulator, so blocking IL-23 may better interrupt the inflammatory cascade that leads to disease. Several recent studies are cited showing lower rates of psoriatic arthritis in patients treated with IL-23 inhibitors compared with IL-17 or TNF inhibitors, though critics argue this may reflect selection bias because higher-risk patients are more likely to receive IL-17 blockers. The speaker counters that the volume of consistent data, along with biologic plausibility and prospective research underway, supports the conclusion that IL-23 inhibitors probably do a better job of preventing psoriatic arthritis.

View more

Conclusions

  • The presentation concludes that IL-23 inhibitors are likely better than IL-17 inhibitors for preventing, rather than treating, the development of psoriatic arthritis in patients with psoriasis.
  • Although IL-17 inhibitors may be superior for treating established psoriatic arthritis, especially axial disease, the preventive question favors IL-23 blockade.
  • Multiple observational studies and real-world comparative analyses consistently show lower incident psoriatic arthritis rates in patients treated with IL-23 inhibitors than in those treated with IL-17 or TNF inhibitors.
  • The apparent advantage of IL-23 inhibitors may partly reflect confounding by indication, but the repeated consistency across studies makes a true preventive effect plausible.
  • The biological rationale supports this conclusion because IL-23 sits upstream of IL-17 and may block the inflammatory cascade earlier in disease evolution.
  • Dermatologists have a key opportunity to identify psoriasis patients at higher risk for psoriatic arthritis and potentially intervene before arthritis develops.
  • Patients with obesity, severe psoriasis, nail or scalp disease, uveitis, family history, genetic risk factors, or musculoskeletal symptoms deserve closer monitoring for transition to psoriatic arthritis.
  • A prospective randomized study of guselkumab in at-risk psoriasis patients is underway, but its lack of a TNF or IL-17 comparator limits direct head-to-head preventive conclusions.
  • Overall, the speaker argues that the balance of current evidence and mechanism suggests IL-23 inhibitors probably help prevent psoriatic arthritis better than IL-17 inhibitors.
  • Perez-Chada et al, J Am Acad Dermatol, 2025.
  • Perez Chada et al, Nat Rev Rheumatol, 2021.
  • Wang et al, Pharmaceutics, 2022.
  • Singla et al, Lancet Rheumatol, 2023.
  • Strober et al, J Am Acad Dermatol, 2024.
  • Gisondi et al, Ann Rheum Dis, 2025.
  • Yu et al, BioDrugs, 2025.
  • Rivera-Diaz et al, Actas Dermosifiliogr, 2026.
  • Lin et al., Rheumatology (Oxford), 2026.
  • Merola and Ogdie, Nat Rev Rheumatol, 2021.
  • Haberman et al, BMJ Open, 2022.